Thyrotoxicosis
Recent clinical, regulatory, research and industry developments relating to this disease.
Marketing authorisation: Emcitate (EMA)
What's happening now
An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.
Therapeutic landscape
Therapies with a regulatory footing for this condition, alongside the wider set of agents co-studied with it in the literature.
Original application approval — Emcitate is indicated for the treatment of peripheral thyrotoxicosis in patients with mon… (2025)
Clinical trials
The current development programme across all trial phases.
Regulatory timeline
Drug regulatory events matched to this condition by indication — EMA.
European Medicines Agency (CC BY 4.0). Events are matched to this condition by drug indication text — approvals/updates for drugs indicated for it, not disease-specific acts.
Research activity
Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.
Major themes2
- Evidence-Based Medicine1
- Precision Medicine1
Leading journals2
- European journal of endocrinology1
- Thyroid : official journal of the American Thyroid Association1
Leading researchers8
- Burch HB1
- Cellini M1
- Cooper DS1
- Greenlee MC1
- Lania A1
- Laurberg P1
- Lavezzi E1
- Maia AL1
Affiliations (unnormalised)6
- 1 Massachusetts General Hospital1
- 11 Institute of Nuclear Medicine1
- 5 Departments of Clinical Medicine and Endocrinology1
- Diabetes and Clinical Nutrition1
- Duke University School of Medicine1
- Hospital de Clinicas de Porto Alegre1
Associated genes
Genes associated with this disease in the canonical knowledge graph (Open Targets evidence). Number shows the association score.
Disease biology
Proteins whose encoding gene is associated with this disease, reached through the canonical gene→disease graph. Number shows the gene's association score.
Reference
Authoritative identity, definition & identifiers.
A hypermetabolic syndrome caused by excess THYROID HORMONES which may come from endogenous or exogenous sources. The endogenous source of hormone may be thyroid HYPERPLASIA; THYROID NEOPLASMS; or hormone-producing extrathyroidal tissue. Thyrotoxicosis is characterized by NERVOUSNESS; TACHYCARDIA; FATIGUE; WEIGHT LOSS; heat intolerance; and excessive SWEATING.
- Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
- Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
- Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
- Related entities are derived from literature co-mention (studied together) — associative, not causal.